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Abstract
OBJECTIVES: Studies have emphasized the importance of normal fibrinogen
concentrations in surgical patients. The primary hypothesis of this study was
that fibrinogen levels significantly decrease in on-pump coronary artery bypass
graft (CABG) surgery versus off-pump coronary artery bypass graft (OPCAB)
surgery. The second objective was to show that ROTEM (TEM International,
GmbH, Munich, Germany) rapidly detects these abnormalities compared with
standard tests. DESIGN: A prospective, nonrandomized study. SETTING: A
university hospital. PARTICIPANTS: Forty-two and 62 patients in the CABG
and OPCAB groups, respectively, undergoing first-time bypass surgery were
included. INTERVENTIONS: CABG versus OPCAB surgery. MEASUREMENTS
AND MAIN RESULTS: Routine coagulation tests and ROTEM values were
measured before anesthesia (T0), after the first dose of heparin (T1), after
protamine (T2), upon intensive care unit arrival (T3), and 4 hours postoperatively
(T4). The outcome measures were followe...
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Objectives: Studies have emphasized the importance of
normal fibrinogen concentrations in surgical patients. The
primary hypothesis of this study was that fibrinogen levels
significantly decrease in on-pump coronary artery bypass
graft (CABG) surgery versus off-pump coronary artery by-
pass graft (OPCAB) surgery. The second objective was to
show that ROTEM (TEM International, GmbH, Munich, Ger-
many) rapidly detects these abnormalities compared with
standard tests.
Design: A prospective, nonrandomized study.
Setting: A university hospital.
Participants: Forty-two and 62 patients in the CABG and
OPCAB groups, respectively, undergoing first-time bypass
surgery were included.
Interventions: CABG versus OPCAB surgery.
Measurements and Main Results: Routine coagulation
tests and ROTEM values were measured before anesthesia
(T0), after the first dose of heparin (T1), after protamine (T2),
upon intensive care unit arrival (T3), and 4 hours postoper-
atively (T4). The outcome measures were followed until 4
hours postoperatively. Fibrinogen concentrations were sig-
nificantly lower in the CABG versus the OPCAB group at T2
(170  44 v 243  73 mg/dL, p < 0.001) and T3 (179  42 v
232  68 mg/dL, p < 0.001). This was confirmed by signifi-
cantly lower FIBTEMmaximal clot firmness values at T2 (9
4 v 14  5 mm, p < 0.001) and T3 (9  4 v 13  6 mm, p <
0.001). In the CABG group, patients received significantly
more transfusions of all blood products except fresh frozen
plasma.
Conclusions: Fibrinogen concentration significantly de-
creases after cardiopulmonary bypass. ROTEM helps in its
fast detection.
© 2012 Elsevier Inc. All rights reserved.
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DESPITE MAJOR ADVANCES in cardiac surgery andcardiopulmonary bypass (CPB), patients undergoing car-
diac surgery belong to the subgroup requiring most of the
blood bank resources.1 This is particularly the case in com-
plex cardiac surgery. The transfusion rate in noncomplex
cardiac surgery should be low. However, this depends on the
incidence of preoperative anemia and dual antiplatelet ther-
apy. Therefore, the fast detection of any coagulation abnor-
malities and proper treatment are necessary to limit periop-
erative bleeding and avoid unnecessary transfusion.
The European guidelines for the management of trauma
patients recommend fibrinogen concentrations around 150 to
200 mg/dL.2 However, increased bleeding has been observed in
surgical patients with fibrinogen concentrations exceeding this
latter threshold.3,4 Furthermore, in bleeding cases in which
crystalloids and colloids have been used to maintain normal
blood volume, fibrinogen has been found to be the first coag-
ulation factor to decrease to critically low values.5 The authors
prospectively studied a large group of patients undergoing
first-time coronary artery bypass graft (CABG) surgery with or
without CPB. The first aim of the study was to show that CPB
significantly reduced plasma fibrinogen levels in the on-pump
group (CABG) compared with the off-pump coronary artery
bypass (OPCAB) group. The second objective was to show that
the point-of-care whole-blood coagulation test ROTEM (TEM
International, GmbH, Munich, Germany) can detect these ab-
normalities very soon compared with standard coagulation
tests.
METHODS
This study was approved by La Commission d’Ethique Biomédicale
Hospitalo-Facultaire de l’UCL, Brussels, Belgium (Belgian registration
number: B40320085181; 2008/10DEC/350; Chairperson: Prof. J.M.
Maloteaux) on December 10, 2008. The trial was registered with
http://Clinicaltrials.gov (identifier: NCT 00825981). Written informed
consent was obtained for each participating patient.
Patients older than 18 years undergoing CABG surgery with or without
CPB between January 2009 and November 2009 were considered for the
study. Exclusion criteria were the following: emergency surgery, redo
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and/or combined surgery, a history of coagulation disorders, preoperative
renal dysfunction (serum creatinine 2.0 mg/dL), or preoperative im-
paired liver function (aspartate and/or alanine aminotransferase 30 U/L).
Patients with a history of autoimmune disease and malignancy were
excluded as well. Two senior surgeons familiar with both techniques were
in charge of the surgery. The decision to perform on- or off-pump surgery
was left to the discretion of the surgeon. Because OPCAB surgery has
gained much interest and is the technique of choice in the authors’
institution, there were more patients in the OPCAB group.
All the patients underwent median sternotomy. Patients in the CABG
group underwent normothermic CPB at a standardized continuous non-
pulsatile flow of 2.2 to 2.4 L/min/m2. The CPB circuit was primed with
1,000 mL of Ringer’s acetate solution (Plasmalyte; Baxter, SA Lessines,
Belgium), 500 mL of hydroxyethyl starch solution (Voluven, Fresenius
Kabi, Belgium), 5,000 U of heparin, and 0.5 g/kg of mannitol. Myocardial
protection was achieved by the induction of electromechanical arrest with
warm blood enriched with potassium chloride and magnesium sulfate.
Heparinization aimed to maintain the kaolin-activated coagulation time
(HR-ACT; Medtronic Inc, Minneapolis, MN) above 400 seconds before
venous cannulation and during the whole CPB time. In patients undergo-
ing OPCAB surgery, heparin was administered to obtain a perioperative
ACT of 300 seconds. Subjects undergoing OPCAB surgery were kept
warm by the intraoperative administration of warm fluids. Complete re-
vascularization was achieved in both groups. After the completion of
anastomoses, protamine sulfate (1,400 antiheparin IU/mL; Leo Pharma,
Dublin, Ireland) was administered at a dose to achieve near preoperative
ACT values.
Anesthesia was induced with midazolam, sufentanil, and propofol and
continued with either propofol or sevoflurane. Muscle relaxation was
achieved with rocuronium. All patients received cefamandole as antibiotic
prophylaxis. In all patients, tranexamic acid was administered at a dose of
15 to 20 mg/kg before the incision. In patients undergoing surgery with
CPB, the same dose was administered in the CPB prime. The intra- and
postoperative intravascular volume replacement were left to the discretion
of the physician in charge of the patient and were performed with crys-
talloids (Plasmalyte), hydroxyethyl starch solutions (Voluven at a maximal
dose of 30 mL/kg) or gelatins (Gelofusine; Fresenius Kabi, Schelle,
Belgium), and salvaged blood from cell saver devices. The red blood cell
transfusion trigger was a hemoglobin concentration of 6.5 g/dL on CPB
and 7.5 g/dL off bypass unless signs of poor tolerance developed. The
transfusion of non–red blood cell components and fibrinogen concentrate
was performed only if clinical bleeding (200 mL/h over 2 consecutive
hours) was present in conjunction with abnormal point-of-care coagulation
tests. Clinical bleeding also was diagnosed if the surgeons could not
visualize clots in the surgical field after protamine injection.
Whole blood drawn from a radial artery was collected in tubes contain-
ing trisodium citrate and was sent to the laboratory via a pneumatic system
for the routine laboratory tests. Fibrinogen was measured according to the
Clauss system. Blood samples were obtained at 5 time points: before the
induction of anesthesia (T0), after the first dose heparin injection (T1), 15
minutes after protamine injection (T2), upon intensive care unit (ICU)
arrival (T3), and 4 hours postoperatively (T4). Blood samples for the blood
cell count, routine coagulation analysis, and ROTEM were performed at
each time point. At T0, blood also was drawn for an anti-Xa assay and
point-of-care whole-blood impedance platelet aggregometry (Multiplate;
Verum Diagnostica GmbH, Munich, Germany). For ROTEM, the authors
investigated 2 activated tests: the EXTEM and the FIBTEM. They were
performed with 300 L of citrated blood and 20 L of 0.2 mol/L calcium
chloride with rabbit brain thromboplastin as an activator with the EXTEM
test and cytochalasin D as an activator with the FIBTEM test. The
ROTEM parameters measured included the coagulation time (CT), clot
formation time (CFT), maximal clot firmness (MCF), and maximum of
lysis (ML) for the EXTEM test and MCF for the FIBTEM test. The normal
values were consistent with previously published data.6 The tubes were
brought manually to the blood bank where the ROTEM analysis was
performed by specialized personnel. The physicians in charge of the
patients were able to interpret the ROTEM results.
For the Multiplate test, the following agonists were used: the aden-
osine diphosphate (ADP) test, the arachidonic acid (ASPI) test, and the
thrombin receptor-activating peptide (TRAP) test. To limit the number
of blood analyses and because the authors focused on immediate
postoperative coagulation abnormalities, all the patients were followed
until 4 hours postoperatively, at which time the last laboratory tests
were performed for the purposes of the study.
A previous observation of the patients undergoing CABG surgery
with CPB revealed mean 4-hour postoperative fibrinogen concentra-
tions of 200  56 mg/dL (unpublished data). The primary goal was to
show a fibrinogen difference of 50 mg/dL between the CABG and the
OPCAB groups. For a power of 0.8 and an  of 0.05, 40 patients were
required in each group. The authors decided to include at least 100
consecutive patients. All the data are expressed as mean  standard
deviation, median and interquartile range, or numbers and percentages as
appropriate. Dichotomous parameters were analyzed using the Fisher exact
test. All the variables were tested for normal distribution using the Kolm-
ogorov-Smirnov test. A Student t test was used for data with a normal
distribution. Continuous nonparametric data were analyzed with the Mann-
Whitney U rank sum test with Bonferroni post hoc analysis. A Friedman
analysis of variance test was used for nonparametric paired data with the
time as the within factor and the group as the between factor. A linear
regression analysis with the Pearson correlation coefficient was computed
to analyze the correlation between continuous data. Statistical analysis was
performed using Statistica (Data Analysis Software System, 2004) version
7 (StatSoft, Tulsa, OK). Statistical significance was accepted when p was
0.05. All p values were 2 tailed.
RESULTS
Figure 1 shows the study flow. A total of 104 patients were
included, with 42 patients undergoing CABG surgery with CPB
and 62 undergoing OPCAB surgery. Table 1 shows the preop-
erative demographic data. Table 2 displays the preoperative
medications. Forty patients (95%) in the CABG group and 55
patients (89%) in the OPCAB arm took a daily dose of aspirin.
Among these subjects, 25% and 16%, respectively, in the
CABG and OPCAB groups had stopped their preoperative
aspirin. The mean duration of the cessation was 6 days. Eight
patients in the CABG group and 15 patients in the OPCAB
group took a daily dose of 75 mg of clopidogrel, which was
stopped in each of them at least 5 days preoperatively. Accord-
ing to the institutional guidelines, the last dose of low–molec-
ular-weight heparin was injected the evening before the sur-
gery. In the CABG group, the mean duration of the CPB time
and the aortic cross-clamp time were 102  35 and 73  35
minutes, respectively. The mean volume used for the CPB
(priming included) consisted of Voluven (832  449 mL),
Plasmalyte (828  283 mL), and Gelofusine (186  358 mL).
There was no significant difference in the number of arterial
grafts (p  0.53) and venous grafts (p  0.13) between both
groups. The number of distal anastomoses was significantly
higher in the CABG group (p  0.008). The amount of cell
saver was significantly higher in the CABG group. It should be
noted that in all the patients undergoing cardiac surgery with
CPB, the blood remaining in the bypass machine was salvaged
at the end of the surgery and administered at the skin closure.
The results of perioperative coagulation tests are shown in
Table 3. Patients in the CABG group showed significantly more
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disturbed coagulation tests after protamine injection and in the
immediate postoperative period compared with the OPCAB
group. This was confirmed by the EXTEM results shown in
Table 4. The prolongation of the coagulation time in EXTEM
reached statistical significance, and this prolongation resulted
in a therapeutic intervention in case of ongoing bleeding. The
main finding of this study was that among the routine coagu-
lation tests, the plasma fibrinogen concentrations were signif-
icantly lower in the CABG group compared with the OPCAB
group after protamine injection (ie, 170  44 mg/dL; 95%
confidence interval [CI], 156-184 v 243  73 mg/dL; 95% CI,
223-262; p  0.001) and upon ICU arrival (179  42 mg/dL;
95% CI, 167-193 v 232  68 mg/dL; 95% CI, 215-249; p 
0.001; Table 3). Concomitant with these results, the FIBTEM
MCF values also were disturbed significantly in the CABG
group versus the OPCAB group (Fig 2). After heparin reversal,
the MCF values of the FIBTEM test in the CABG group were
9  4 mm (95% CI, 8-11) versus 14  5 mm (95% CI, 12-15)
in the OPCAB group (p  0.001). Upon ICU arrival, the
CABG group showed FIBTEM-related MCF values of 9  4
mm (95% CI, 7-10) versus 13  6 mm (95% CI, 11-14) in the
OPCAB arm (p 0.001). The delta decrease in FIBTEM MCF
values between T2 and T0 and between T3 and T0 were
significantly higher in the CABG group compared with the
OPCAB group (p  0.004 and p  0.001, respectively).
Although the serum fibrinogen concentrations were above the
Fig 1. Study flow.
Table 1. Preoperative Characteristics of Patients
CABG (n  42) OPCAB (n  62) p Value
Age (y), mean  SD 66  11 68  11 0.35
Weight (kg), mean  SD 79  16 79  15 0.99
Sex male 31 (73) 41 (66) 0.65
Hb (g/dL), mean  SD 13.4  1.7 12.9  1.7 0.16
Creatinine (mg/dL), mean  SD 1.08  0.3 1.11  0.37 0.65
Arterial hypertension 35 (83) 48 (77) 0.47
Hypercholesterolemia 33 (79) 52 (84) 0.61
Active smoking 9 (21) 14 (23) 0.99
Diabetes 10 (24) 18 (29) 0.65
Previous MI 14 (33) 24 (39) 0.68
Ejection fraction (%) 54  13 55  13 0.73
Log EuroSCORE, median (95% CI) 2.23 (1.7-4.09) 3.36 (2.32-4.81) 0.17
NOTE. Data are expressed as numbers and percentages in brackets unless otherwise stated.
Abbreviations: Hb, hemoglobin; MI, myocardial infarction; Log EuroSCORE, logistic EuroSCORE.
Table 2. Preoperative Medications
CABG (n  42) OPCAB (n  62) p Value
Aspirin 40 (95) 55 (89) 0.52
Aspirin stopped
preoperatively 10 (25) 8 (16) 0.29
Clopidogrel* 8 (19) 15 (24) 0.63
LMWH 11 (26) 22 (35) 0.39
Beta blocker 32 (76) 50 (81) 0.63
Ca antagonist 6 (14) 15 (24) 0.32
ACE inhibitor 26 (62) 40 (65) 0.84
Nitrate 17 (40) 22 (35) 0.68
Statin 33 (79) 48 (77) 0.99
Diuretics 9 (21) 15 (24) 0.82
NOTE. Data are expressed in numbers and percentages in brackets.
Abbreviation: LMWH, low–molecular-weight heparin.
*Clopidogrel was stopped in all the patients at least 5 days preop-
eratively.
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trigger values of 100 mg/dL, the authors administered human
fibrinogen concentrate to stop bleeding in 5 patients in the
CABG group (Table 5). This decision was based on the patho-
logic FIBTEM results. Two patients who received human fi-
brinogen concentrate also received fresh frozen plasma based
on the pathologic ROTEM results. None of the patients in the
OPCAB group required fibrinogen concentrate.
The CABG group showed significantly lower platelet num-
bers upon ICU arrival. This was confirmed again by the results
of the EXTEM test, which were more pathologic in the CABG
group. Significantly more patients in the CABG group also
required transfusion of platelets based on the EXTEM results.
The administration of blood products mainly was performed in
the operating room. It should be noted that the results of the
Multiplate realized at baseline did not show any significant
differences between groups. In the CABG group, 48%, 74%,
and 38% had abnormal ADP, ASPI, and TRAP test results,
respectively. In the OPCAB arm, 48%, 77%, and 37% showed
abnormal ADP, ASPI, and TRAP test results, respectively.
There was no correlation between the baseline Multiplate tests
and the transfusion requirements. The Multiplate test was only
performed at baseline; therefore, the platelet function was not
evaluated after CPB to predict the need for platelet transfusion.
No correlation could be observed between the duration of CPB
and the decrease in FIBTEM MCF values. The authors did not
find any correlation between FIBTEM MCF values and the
transfusion of blood products. Interestingly, immediate postop-
erative bleeding was not significantly different between the 2
groups as shown in Table 5. One patient in each group needed
revision for bleeding. The bleeding was revealed to be of a
surgical origin in both patients.
DISCUSSION
The main finding of this study was that compared with the
OPCAB group, CPB significantly decreased plasma fibrin-
ogen levels although other coagulation tests also showed
some abnormalities. The decrease in plasma fibrinogen lev-
els was significant after the protamine injection and upon
Table 3. Results of Coagulation, Multiplate, and Anti-Xa Tests at Several Time Points
Baseline Heparin Injection Protamine Injection ICU Arrival 4 h Postoperatively
Multiplate
CABG
AUC ADP 650  290
AUC ASPI 358  260
AUC TRAP 939  267
OPCAB
AUC ADP 598  303
AUC ASPI 327  297
AUC TRAP 970  343
Anti-Xa
CABG 0.06  0.12
OPCAB 0.08  0.13
Hb(g/dL)
CABG 12.7  1.7 11.2  1.5* 8.6  1.3*‡ 10.3  1.3* 10.0  1.2*
OPCAB 12.1  1.7 10.8  1.6* 9.7  1.5* 10.0  1.4* 10.0  2.1*
Platelet count (1,000/mL)
CABG 227  69 208  58* 126  51* 137  36*† 136  39*
OPCAB 212  51 198  49* 136  46* 156  45* 147  41*
PT (s)
CABG 11.3  0.7 20.8  5.7*‡ 14.6  1.3*† 12.8  1.0*† 12.1  0.6*†
OPCAB 11.1  0.5 15.1  1.6* 13.8  1.1* 12.3  0.7* 11.7  0.8*
aPTT (s)
CABG 26.3  2.8 180* 34.7  6.6*† 35.9  23.3*† 37.2  12.3*†
OPCAB 25.6  2.1 180* 31.9  3.7* 29.5  3.6* 31.6  5.8*
INR
CABG 1.04  0.05 1.99  0.59* 1.37  0.12*† 1.91  0.09*† 1.22  0.05*†
OPCAB 1.02  0.05 1.41  0.15* 1.29  0.11* 1.15  0.07* 1.08  0.07*
Fibrinogen
CABG 318  69 265  60* 170  44*‡ 179  42*‡ 198  50*
OPCAB 357  98 307  83* 243  73* 232  68* 231  81*
NOTE. Data are expressed as mean  standard deviation.
Abbreviations: Hb, hemoglobin; PT, prothrombin time; aPTT, activated partial thromboplastin time; INR, international normalized ratio; AUC
ADP, area under curve adenosine diphosphate test (normal range: 607-963); AUC ASPI, area under curve arachidonic acid test (normal range:
505-1,086); AUC TRAP, area under curve thrombin receptor-activating peptide, area under curve thrombin receptor activating peptide (normal
range: 868-1,473).
*p  0.001 within group.
†p  0.05 between groups.
‡p  0.001 between groups.
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ICU arrival. The authors were able to treat hemostasis per-
turbations within 4 hours postoperatively. These observa-
tions agreed with previous studies in which fibrinogen was
the first coagulation test to decline after major surgery.5 This
was mainly because of the hemodilution of CPB and blood
loss.7 The present findings also confirmed the widely ac-
cepted concept that CPB may result in impaired coagulation.
The results of this study are in line with the available data
showing the impact of OPCAB on transfusion requirements
and/or postoperative bleeding.8,9
The decrease in coagulation parameters was confirmed by
the EXTEM and FIBTEM tests. Interestingly, the low fibrin-
ogen concentrations in the CABG group, which still ex-
ceeded the trigger value of 100 mg/dL, corresponded to the
pathologic FIBTEM results. As expected, the EXTEM and
FIBTEM results were both significantly more pathologic in
the CABG group. It should be noted that the baseline fibrin-
ogen levels of patients in the CABG group were lower than
the OPCAB group although they were not significantly dif-
ferent (p  0.06). Previous studies in cardiac surgery have
shown an inverse relationship between preoperative plasma
fibrinogen levels and postoperative bleeding.3,10 This was
not the case in the present study because the coagulation
abnormalities were corrected very rapidly. By contrast, the
delta decrease in FIBTEM compared with baseline was higher in
the CABG group versus the OPCAB group. This shows that the
relative decrease in fibrinogen concentrations might be an impor-
tant factor as well.
Table 4. EXTEM Values at Several Time Points
EXTEM Variable Baseline Heparin Injection Protamine Injection ICU Arrival 4 h Postoperatively
CT (s, normal range: 42-74)
CABG 55 (50-61) 103 (86-129)† 78 (70-85)† 67 (60-80)† 69 (62-77)†
OPCAB 53 (47-59) 95 (80-113)† 73 (64-83)† 62 (55-70)†‡ 60 (54-72)†‡
CFT (s, normal range: 46-148)
CABG 74 (60-85) 97 (70-122)† 135 (104-188)† 123 (108-147)† 125 (101-151)†
OPCAB 64 (52-81) 74 (63-99)†‡ 103 (74-127)†‡ 96 (82-134)†‡ 99 (78-135)†‡
MCF (mm, normal range: 49-71)
CABG 63 (60-66) 61 (60-65)* 55 (49-60)† 55 (51-58)† 55 (52-59)†
OPCAB 64 (60-67) 64 (60-68)* 57 (54-62)†‡ 58 (54-62)†‡ 59 (54-63)†‡
ML (%, normal range: 0-15)
CABG 16 (11-19) 9 (5-12)† 10 (7-14)† 10 (8-15)* 11 (8-15)*
OPCAB 14 (11-19) 11 (7-17)*‡ 12 (8-16)* 11 (8-14)* 14 (10-17)
NOTE. Data are expressed as median (25th percentile-75th percentile).
Abbreviations: CT, coagulation time; CFT, clot formation time; MCF, maximal clot firmness; ML, maximum of lysis.
*p  0.05 within group.
†p  0.001 within group.
‡p  0.05 between groups.
Fig 2. FIBTEM MCF results at several time points. Box and whisker plots of FIBTEM MCF values. The boxes represent the lower (25th) and
upper (75th) quartiles, and the horizontal line represents the median. The whiskers extend to the 1.5 interquartile range. The outliers are plotted
as a circle. Dashed lines indicate the normal range of FIBTEM MCF. FibtemMCF0, T0; FibtemMCF1, T1; FibtemMCF2, T2; FibtemMCF3, T3;
FibtemMCF4, T4. **p < 0.001 within group. †p < 0.05 between groups. ††p < 0.001 between groups.
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The second important observation of this study was that,
based on the ROTEM results,6 the authors were able to
detect the coagulation abnormalities within 20 minutes and
substitute the necessary coagulation factors. The FIBTEM
results were particularly helpful in the decision to administer
fibrinogen concentrate. Five bleeding patients in the CABG
group received 1 g of lyophilized fibrinogen concentrate
each, after which the bleeding was stopped. These results
highlight the importance of high normal fibrinogen concen-
trations in the maintenance of normal hemostasis. Indeed, in
recent years, much attention has been focused on the critical
role of fibrinogen in the coagulation cascade.11,12 Therefore,
numerous studies in cardiac surgery have been conducted,
aiming to prevent bleeding by transfusing high doses of
fibrinogen concentrate.13-15 However, the dose of fibrinogen
concentrate administered in this study was much lower than
that in the studies of Rahe-Meyer et al.13,14 The present
authors administered fibrinogen only if the FIBTEM MCF
was 9 mm. This is in contrast to previous studies in which
FIBTEM MCF values of 22 mm were targeted. In the latter
studies, the authors aimed to reduce the use of fresh frozen
plasma and platelet concentrates by targeting high FIBTEM
MCF values.
An important point to be considered is that there was no
significant difference in the postoperative bleeding of the
groups during the first 4 hours after arrival in the ICU. The
authors believe this was the result of fast and rational
transfusion of the necessary coagulation factors. Although in
several countries the use of blood products is predominant
for cardiovascular surgery,1 there is a wide variation regard-
ing the blood conservation and transfusion policy in this
field.16 A rational hemostatic therapy guided by point-of-
care testing seems mandatory in cardiac surgery. In a very
recent retrospective study, the use of point-of-care testing
was associated with a decreased incidence of blood transfu-
sion and thrombotic/thromboembolic events.17 Although the
primary endpoint of the present study was not the incidence
of intraoperative allogeneic blood transfusion and it was not
designed to compare a ROTEM-guided transfusion group
with a control group, the authors believe that unnecessary
re-exploration and major postoperative bleeding were
avoided by the fast administration of adequate coagulation
factors. These results are in line with other studies showing
the benefits of ROTEM-guided transfusion policy in the
management of patients at high risk of transfusion.18-21
This was a nonrandomized prospective study. The main
aim of this study was to underline the importance of fibrin-
ogen levels in achieving hemostasis and, in particular, in
surgery with CPB. However, no bias could be excluded
because the decision in terms of type of surgery was only
made by the surgeon. Another important point to consider is
that the physicians in charge of the patients were not blinded
to the ROTEM results. Hence, a prospective, randomized,
double-blind study should be encouraged to further prove
the superiority of ROTEM compared with traditional coag-
ulation tests in cardiac surgery. The nonblinded aspect of
this study was also the reason why the authors could not find
a correlation between FIBTEM MCF results and the trans-
fusion requirements because these values already were used
to guide the therapy with fibrinogen concentrate. It would be
Table 5. Intra- and Postoperative Characteristics of Patients
CABG (n  42) OPCAB (n  62) p Value
Number of patients transfused with packed RBC (%) 26 (62) 23 (37) 0.02
Number of patients transfused with platelets (%) 8 (19) 1 (2) 0.001
Number of patients transfused with FFP (%) 7 (17) 3 (5) 0.09
Number of patients transfused with fibrinogen (%) 5 (12) 0 0.001
Units packed RBC transfused, median (IQR) 3 (2,4) 2 (1,3) 0.02
Units platelets transfused, median (IQR) 12 (11,13) 0 0.001
Units FFP transfused, median (IQR) 2 (2,3) 3 (2,3) 0.06
Intraoperative cell salvage, mL 728  230 360  374 0.001
Voluven, mL
Intraoperative (CPB volume excluded) 656  465 1155  442 0.001
Postoperative 630  429 533  382 0.09
Gelofusin, mL
Intraoperative (CPB volume excluded) 60  198 48  149 0.99
Postoperative 488  374 510  327 0.5
Plasmalyte, mL
Intraoperative (CPB volume excluded) 785  380 1146  442 0.001
Postoperative 0 0
Number of revisions for bleeding 1 1 NS
Postoperative bleeding
First hour, mL 86  80 64  68 0.08
Second hour, mL 92  169 47  32 0.06
Third hour, mL 64  71 55  50 0.26
Fourth hour, mL 58  57 40  32 0.08
Cumulative 4-h blood loss, mL 295  286 204  133 0.23
NOTE. Data are expressed as mean  standard deviation unless otherwise stated.
Abbreviations: RBC, red blood cell; FFP, fresh frozen plasma; IQR, interquartile range; NS, not significant.
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interesting to investigate whether there was a correlation
between ROTEM values and blood loss before any correc-
tion with fibrinogen. It should be noted that the “classic”
transfusion algorithm was not followed in 5 patients in the
CABG group with respect to the administration of human
fibrinogen concentrate because the serum fibrinogen concen-
trations were above the trigger value of 100 mg/dL. Finally,
this study was stopped at 4 hours postoperatively. There-
fore, the recovery of coagulation tests after 24 hours has not
been investigated.
In summary, the results of this study showed the detrimental
effects of CPB on the coagulation parameters and, in particular,
the fibrinogen concentrations. Point-of-care tests are helpful in
the early detection of these abnormalities. This will guide
physicians in the administration of the required transfusion
products.
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